Levels and determinants of COVID-19 vaccine hesitancy among sub-Saharan African

2 adolescents

1

3

- 4 Dongqing Wang¹¶*, Angela Chukwu²¶, Mary Mwanyika-Sando³¶, Sulemana Watara Abubakari⁴,
- Nega Assefa⁵, Isabel Madzorera¹, Elena C Hemler¹, Abbas Ismail⁶, Bruno Lankoande⁷, Frank 5
- Mapendo³, Ourohiré Millogo⁸, Firehiwot Workneh⁹, Temesgen Azemraw⁹, Lawrence G Febir⁴, 6
- 7 Christabel James¹⁰, Amani Tinkasimile³, Kwaku Poku Asante⁴, Till Baernighausen^{1,11,12},
- Yemane Berhane⁹, Japhet Killewo¹³, Avoade M.J. Oduola¹⁰, Ali Sie⁸, Emily R Smith^{14,15}, 8
- Abdramane Bassiahi Soura⁷, Raji Tajudeen¹⁶, Said Vuai^{6†}, Wafaie W Fawzi^{1,17,18†*} 9
- 11 ¹Department of Global Health and Population, Harvard T.H. Chan School of Public Health,
- 12 Harvard University, Boston, Massachusetts, United States of America
- ²Department of Statistics, University of Ibadan, Ibadan, Nigeria 13
- ³Africa Academy for Public Health, Dar es Salaam, Tanzania 14
- 15 ⁴Kintampo Health Research Centre, Research and Development Division, Ghana Health Service,
- Kintampo North Municipality, Bono East Region, Ghana 16
- 17 ⁵College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia
- ⁶College of Natural and Mathematical Sciences, University of Dodoma, Dodoma, Tanzania 18
- 19 ⁷Institut Supérieur des Sciences de la Population, University of Ouagadougou, Ouagadougou,
- 20 Burkina Faso
- ⁸Nouna Health Research Center, Burkina Faso 21
- 22 ⁹Addis Continental Institute of Public Health, Ethiopia
- 23 ¹⁰University of Ibadan Research Foundation, University of Ibadan, Ibadan, Nigeria

24 ¹¹Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany 25 ¹²Africa Health Research Institute, KwaZulu-Natal, South Africa 26 ¹³Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied 27 Sciences, Dar es Salaam, Tanzania 28 ¹⁴Department of Global Health, Milken Institute School of Public Health, George Washington 29 University, Washington, DC, United States of America 30 ¹⁵Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, 31 George Washington University, Washington, DC, United States of America 32 ¹⁶Division of Public Health Institutes and Research, Africa Centres for Disease Control and 33 Prevention, Addis Ababa, Ethiopia ¹⁷Department of Nutrition, Harvard T.H. Chan School of Public Health, Harvard University, 34 35 Boston, Massachusetts, United States of America ¹⁸Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, 36 37 Boston, Massachusetts, United States of America 38 39 These authors contributed equally to this work as first authors. 40 † These authors contributed equally to this work as last authors. 41 * Joint corresponding authors: 42 43 E-mail: dqwang@hsph.harvard.edu (DW) 44 mina@hsph.harvard.edu (WWF) 45 Short title: COVID-19 vaccine hesitancy in sub-Saharan African adolescents

Abstract

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

COVID-19 vaccine hesitancy among adolescents poses a challenge to the global effort to control the pandemic. This multi-country survey aimed to assess the levels and determinants of COVID-19 vaccine hesitancy among adolescents in sub-Saharan Africa between July and December 2021. The survey was conducted using computer-assisted telephone interviewing among adolescents in five sub-Saharan African countries, Burkina Faso, Ethiopia, Ghana, Nigeria, and Tanzania. A rural area and an urban area were included in each country (except Ghana, which only had a rural area), with approximately 300 adolescents in each area and 2803 in total. Sociodemographic characteristics and perceptions and attitudes on COVID-19 vaccines were measured. Vaccine hesitancy was defined as definitely not getting vaccinated or being undecided on whether to get vaccinated if a COVID-19 vaccine were available. Log-binomial models were used to calculate the adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) for associations between potential determinants and COVID-19 vaccine hesitancy. The percentage of COVID-19 vaccine hesitancy was 15% in rural Kersa, 24% in rural Ibadan, 31% in rural Nouna, 33% in urban Ouagadougou, 37% in urban Addis Ababa, 48% in rural Kintampo, 64% in urban Lagos, 76% in urban Dar es Salaam, and 88% in rural Dodoma. Perceived low necessity, concerns about vaccine safety, and concerns about vaccine effectiveness were the leading reasons for hesitancy. Healthcare workers, parents or family members, and schoolteachers had the greatest impacts on vaccine willingness. Perceived lack of safety (aPR: 3.61; 95% CI: 3.10, 4.22) and lack of effectiveness (aPR: 3.59; 95% CI: 3.09, 4.18) were associated with greater vaccine hesitancy. The levels of COVID-19 vaccine hesitancy among adolescents are alarmingly high across the five sub-Saharan African countries, especially in Tanzania. COVID-19

- vaccination campaigns among sub-Saharan African adolescents should address their concerns
- and misconceptions about vaccine safety and effectiveness.
- 72 **Keywords:** COVID-19; vaccines; vaccine hesitancy; adolescents; sub-Saharan Africa; telephone
- 73 survey

Introduction

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

With unprecedented speed, multiple vaccines against SARS-CoV-2 were developed one year after the beginning of the coronavirus disease 2019 (COVID-19) pandemic. While the COVID-19 vaccination campaigns worldwide continue with the immunization of adults, COVID-19 vaccines have been or may be made available to adolescents in many settings. The United States Centers for Disease Control and Prevention currently recommends the Pfizer-BioNTech COVID-19 vaccine to children and adolescents ages 5 to 17 years old [1]. The morbidity and mortality from COVID-19 are much lower in adolescents than among adults, especially when compared to the most vulnerable group aged 65 years and older [2]. However, there is a strong rationale for providing COVID-19 vaccines to children and adolescents. Infected adolescents can still transmit the virus to other individuals [3], and some adolescents do themselves develop severe symptoms and complications from COVID-19 [4-6]. Therefore, vaccinating the adolescent population has the dual benefits of protecting adolescents against morbidity and mortality while reducing the spread of the virus by promoting herd immunity [3, 7]. In sub-Saharan Africa, adolescents aged 10 to 19 years make up 23% of the population [8]. Therefore, getting COVID-19 vaccines into the arms of adolescents is crucial for Africa to achieve the World Health Organization's target of 70% COVID-19 vaccination coverage by mid-2022 [9]. Further, adolescents may serve as agents of advocacy that encourage their family members and friends to get vaccinated [10]. Existing evidence shows that COVID-19 vaccines are safe and effective in adolescents [11]. However, studies in high-income settings show the concerning issue of COVID-19 vaccine hesitancy among adolescents. A survey conducted by the United States Centers for Disease Control and Prevention among adolescents and their parents in April 2021 (just before the

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

expanded availability of the Pfizer-BioNTech vaccine to adolescents) showed that only 52% of unvaccinated adolescents aged 13 to 17 years would definitely or probably receive a COVID-19 vaccine [12]. Vaccine hesitancy, defined as the reluctance to accept available vaccines [13], was considered by the World Health Organization as one of the top threats to global health even before the COVID-19 pandemic [14]. Vaccine hesitancy of adolescents poses a challenge to the global effort to control the COVID-19 pandemic. Perceptions and attitudes toward vaccines are heavily driven by cultural, social, historical, political, and individual factors that greatly vary across cultural and geographical settings [15]. As a result, COVID-19 vaccine hesitancy varies considerably across regions and countries, as shown repeatedly in previous surveys among adults [16-21]. Further, the levels and determinants of vaccine hesitancy in adults may not match those among adolescents [22]. Previous studies on COVID-19 vaccine hesitancy of adolescents were conducted in high-income countries [12, 22-25] and China [10], whereas studies in sub-Saharan African countries [19, 26-32] and other LMICs [31, 33-43] have primarily examined the adult population. To the best of our knowledge, no study has specifically examined the levels and determinants of COVID-19 vaccine hesitancy among adolescents across diverse settings in sub-Saharan Africa, a region where adolescents make up a considerable share of the population [44]. With the COVID-19 vaccination efforts around the globe moving toward children and adolescents, a better understanding of the extent and the driving factors of vaccine hesitancy in adolescents is needed to devise vaccination campaigns that increase vaccine uptake among adolescents. In this telephone survey across five sub-Saharan African countries, we aimed to assess the levels of COVID-19 vaccine hesitancy in adolescents and evaluate the potential determinants of adolescent COVID-19 vaccine hesitancy.

Methods

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

Study design and study population

This cross-country study was based on an ongoing survey that used a novel mobile platform and computer-assisted telephone interviewing to collect data from sub-Saharan African adolescents, adults, and healthcare providers. In the previous round of the survey (Round 1), six areas from three countries were included, namely Nouna and Ouagadougou in Burkina Faso, Kersa and Addis Ababa in Ethiopia, and Ibadan and Lagos in Nigeria. In each country, one rural area (Nouna, Kersa, and a rural subarea in Ibadan) and one urban area (Ouagadougou, Addis Ababa, and Lagos) were included. The details of the study design and study population in Round 1 were described previously [45]. In the currently reported new round (Round 2), a rural subarea in Kintampo (Ghana), a rural subarea in Dodoma (Tanzania), and an urban subarea in Dar es Salaam (Tanzania) were added as new participating areas. Therefore, the Round 2 survey included nine areas from five countries. Although Ibadan and Dodoma are generally considered urban, the surveys were conducted in more rural subareas of Ibadan and Dodoma. The countries and areas were selected based on existing collaborations and infrastructure available in the African Research, Implementation Science and Education (ARISE) Network [46] to represent diverse settings across sub-Saharan Africa. The detailed study protocol of the Round 2 survey is available on the website of the Harvard University Center for African Studies (https://africa.harvard.edu/files/africanstudies/files/arise covid survey round 2 methods brief final.pdf). Briefly, during Round 2, households were selected from sampling frames of existing Health and Demographic Surveillance Systems (HDSSs) or national surveys, where possible. Within the sampling frame in each area, we interviewed approximately 300 randomly selected households with adolescents

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

between the ages of 10 to 19 years residing in the household. The sampling frames and sampling methods for Burkina Faso, Ethiopia, and Nigeria have been described in detail previously [45]. For the new study area of Kintampo (Ghana), we used the Kintampo HDSS as the sampling frame. The Kintampo HDSS represents a catchment area of 163182 individuals and 39134 households. A total of 3589 adolescents were randomly sampled from the overall list of households, and 1074 households were called until the target sample size of 300 adolescents was reached. For the new study area of Dodoma (Tanzania), we used the Dodoma HDSS as the sampling frame; 600 households with adolescents were selected randomly from the sampling frame, and 318 eligible adolescents completed the survey. For the new study area of Dar es Salaam (Tanzania), we used the Dar es Salaam HDSS, also referred to as the Dar es Salaam Urban Cohort Study (DUCS) [47], as the sampling frame. The Dar es Salaam HDSS included 14754 households comprised of 143452 individuals, of which 30446 were adolescents. We randomly selected 2500 households, and approximately 655 households were contacted to attain the sample size of 302 adolescents. The Round 1 survey was conducted between July and November 2020, and the Round 2 survey was conducted between July and December 2021. For the Round 2 survey, all households with adolescents aged 10 to 19 years that participated in the Round 1 survey were contacted again. A small number of participants aged 19 years during Round 1 and aged 20 years at the time of Round 2 were also eligible for inclusion to enrich the examination of the potential impacts of Round 1 predictors. For households that could not be contacted, new households were randomly identified from the sampling frame until the minimum target sample size of 300 households per area was reached. For Tanzania and Ghana, however, none of the adolescents participated in Round 1, as the two countries were added during the Round 2 survey.

Verbal parental consent and adolescent assent were obtained for adolescents younger than 18 years of age, and oral informed consent was obtained from adolescents aged 18 years and older. This study was approved by the Institutional Review Board at Harvard T.H. Chan School of Public Health and ethical review boards in each country and area, including the Nouna Health Research Center Ethical Committee and National Ethics Committee in Burkina Faso, the Institutional Ethical Review Board of Addis Continental Institute of Public Health in Ethiopia, Kintampo Health Research Centre Institutional Ethics Committee in Ghana, the University of Ibadan Research Ethics Committee and National Health Research Ethics Committee in Nigeria, and the University of Dodoma, Muhimbili University of Health and Allied Sciences, and National Institute for Medical Research in Tanzania.

Data collection

The Round 1 survey included questions on the adolescents' sociodemographic characteristics, knowledge and perceptions of COVID-19, and the impacts of the COVID-19 pandemic on adolescents' education, daily activities, communication, media consumption, and various health domains, including dietary intake and mental health [48]. The Round 2 survey focused heavily on adolescents' awareness, knowledge, perceptions, and attitudes toward COVID-19 vaccines, willingness to receive COVID-19 vaccines, potential determinants of COVID-19 vaccine hesitancy, trusted sources of information regarding COVID-19 vaccines, and the expectations on COVID-19 vaccine campaigns. The complete adolescent instrument used for the Round 2 survey is available on the website of the Harvard University Center for African Studies (https://africa.harvard.edu/files/african-studies/files/arise_covid-19 survey round 2 adolescent household survey questionnaire.pdf).

Statistical analysis

We conducted descriptive analyses on the sociodemographic characteristics of the adolescents, willingness to receive the COVID-19 vaccine, perceptions of the vaccine, self-reported determinants of their willingness to be vaccinated, and their trusted information sources and expectations about the vaccine. For the descriptive analyses, we calculated means and standard deviations (SDs) overall and by area for continuous variables and counts and percentages for categorical variables.

The outcome for the associational analyses was COVID-19 vaccine hesitancy, defined as a response of definitely not getting the COVID-19 vaccine or maybe, unsure, or undecided on whether to get the COVID-19 vaccine if it were available now. We defined vaccine hesitancy as a dichotomous outcome. The potential determinants included age, sex, country, rural residence, currently receiving education, perceived safety of the COVID-19 vaccine among children and adolescents, perceived effectiveness of the COVID-19 vaccine, current impacts of the COVID-19 pandemic on daily activities, levels of psychological distress measured using the four-item Patient Health Questionnaire for Depression and Anxiety Scale [49], perceived risk of being exposed to COVID-19 during Round 1 (for Round 1 participants only), and knowledge score on the symptoms, transmission, and prevention of COVID-19 measured during Round 1 (for Round 1 participants only).

We used log-binomial models to calculate the prevalence ratios (PRs) and 95% confidence intervals (CIs) and modified Poisson models to achieve model convergence whenever necessary [50]. We examined the crude associations between potential determinants and vaccine hesitancy in unadjusted models. We estimated adjusted prevalence ratios (aPRs) in adjusted

models controlled for age, sex, country, and rural residence. We conducted all analyses using SAS 9.4 (SAS Institute Inc., Cary, North Carolina) at a two-sided α level of 0.05. Missing data were handled using the complete case analysis.

216 Results

Sociodemographic characteristics

A total of 2803 adolescents were interviewed (**Table 1**). The age of the adolescents ranged from a minimum of 10 years to a maximum of 20 years. The mean age ranged from 14 years in Dodoma (SD: 2.3) and Dar es Salaam (SD: 2.6) to 17 years in Addis Ababa (SD: 2.4) and Ibadan (SD: 2.0). The sex distributions were roughly balanced between girls and boys, except for Kersa, where 31% were girls, and Addis Ababa, where 62% were girls. The percentage of adolescents with at least some secondary school education ranged from 16% in Dodoma to 96% in Ibadan. No less than 85% of the participants self-identified as students, except in Nouna and Dodoma, where 52% and 57% of the adolescents were students, respectively. In Burkina Faso, Ethiopia, and Nigeria, adolescents who also participated in the Round 1 survey varied from 9% in Lagos to 64% in Addis Ababa.

Table 1 Sociodemographic characteristics of adolescents in a phone-based survey in five sub-Saharan African countries, 2021

	Burki	ina Faso	Ethi	opia	Ghana	Nig	geria	Та	nzania	
	Rural	Urban	Rural	Urban	Rural	Rural	Urban	Rural	Urban	Total
	Nouna	Ouagadougou	Kersa	Addis Ababa	Kintampo	Ibadan	Lagos	Dodoma	Dar es Salaam	
Number of adolescents, N	309	300	300	308	300	319	347	318	302	2803
Adolescents who also participated in	185 (59.9)	181 (60.3)	109 (36.3)	198 (64.3)	0 (0.0)	120 (37.6)	31 (8.9)	0 (0.0)	0 (0.0)	824 (29.4)
Round 1 survey, N (%)										
Age, years (SD)	15.8 (2.5)	15.8 (2.5)	16.1 (2.8)	17.0 (2.4)	15.6 (2.7)	16.9 (2.0)	16.0 (1.9)	14.4 (2.3)	14.1 (2.6)	15.7 (2.6)
Girls, <i>N</i> (%)	140 (45.3)	161 (53.7)	92 (30.7)	191 (62.0)	153 (51.0)	175 (54.9)	206 (59.4)	175 (55.0)	177 (58.6)	1470 (52.4)
Highest level of education, $^{2,3} N$ (%)										
None/religious school/literacy class	38 (12.4)	17 (5.7)	2 (0.7)	1 (0.3)	10 (3.3)	1 (0.3)	0 (0.0)	34 (10.7)	0 (0.0)	103 (3.7)
Some primary school	90 (29.4)	58 (19.3)	139 (46.3)	59 (19.2)	109 (36.3)	3 (0.9)	0 (0.0)	169 (53.1)	109 (36.5)	736 (26.3)
Completed primary school	40 (13.1)	16 (5.3)	30 (10.0)	30 (9.7)	46 (15.3)	9 (2.8)	17 (4.9)	65 (20.4)	52 (17.4)	305 (10.9)
Some secondary/high school	114 (37.3)	186 (62.0)	103 (34.3)	130 (42.2)	127 (42.3)	216 (67.9)	299 (86.2)	48 (15.1)	113 (37.8)	1336 (47.8)
Completed secondary/high school	11 (3.6)	20 (6.7)	10 (3.3)	50 (16.2)	7 (2.3)	78 (24.5)	27 (7.8)	2 (0.6)	19 (6.4)	224 (8.0)

Tertiary education or higher	13 (4.3)	3 (1.0)	16 (5.3)	38 (12.3)	1 (0.3)	11 (3.5)	4 (1.2)	0 (0.0)	6 (2.0)	92 (3.3)
Occupation ⁴ N (%)										
Unemployed	21 (6.8)	12 (4.0)	2 (0.7)	5 (1.6)	11 (3.7)	0 (0.0)	0 (0.0)	71 (22.3)	21 (7.0)	143 (5.1)
Student	161 (52.1)	255 (85.0)	278 (92.7)	290 (94.2)	259 (86.3)	309 (97.5)	342 (98.6)	181 (56.9)	267 (88.4)	2342 (83.6)
Farmer	86 (27.8)	0 (0.0)	16 (5.3)	2 (0.7)	14 (4.7)	0 (0.0)	0 (0.0)	34 (10.7)	1 (0.3)	153 (5.5)
Wage employment	0 (0.0)	2 (0.7)	0 (0.0)	5 (1.6)	3 (1.0)	1 (0.3)	3 (0.9)	0 (0.0)	3 (1.0)	17 (0.6)
Self-employed	7 (2.3)	9 (3.0)	2 (0.7)	6 (2.0)	8 (2.7)	6 (1.9)	2 (0.6)	1 (0.3)	10 (3.3)	51 (1.8)
Casual, off-farm income	6 (1.9)	4 (1.3)	0 (0.0)	0 (0.0)	1 (0.3)	1 (0.3)	0 (0.0)	31 (9.8)	0 (0.0)	43 (1.5)

¹ Values are mean (standard deviation) for age and count (percentage) for other variables. SD, standard deviation.

Willingness to receive COVID-19 vaccines

Over 80% of adolescents had previously heard of COVID-19 vaccines, except in Nouna and Kersa, where 74% and 57% of the adolescents had heard of the vaccines, respectively (**Table 2**). Kersa had the highest percentage of adolescents who would definitely get vaccinated if a COVID-19 vaccine were available (86%), whereas Dodoma had the lowest percentage of willingness to definitely get vaccinated (12%). Correspondingly, Dodoma had the highest percentage of adolescents who would definitely *not* get vaccinated (79%), and Kersa had the lowest percentage (11%). Nouna had the highest percentage of adolescents who were unsure or undecided on whether they would be vaccinated if a COVID-19 vaccine were available (17%). In ascending order, the percentage of adolescents with COVID-19 vaccine hesitancy, defined as definitely not getting vaccinated or unsure/undecided, was 15% in Kersa, 24% in Ibadan, 31% in Nouna, 33% in Ouagadougou, 37% in Addis Ababa, 48% in Kintampo, 64% in Lagos, 76% in Dar es Salaam, and 88% in Dodoma. Among adolescents who were definitely or possibly willing to receive COVID-19 vaccines, keeping themselves and their families safe was the most common reason for vaccination, cited by over 92% of adolescents in all areas except in Dodoma

² Percentages may not add up to 100% due to rounding.

³ Level of education missing for 3 adolescents in Nouna, 1 adolescent in Ibadan, and 3 adolescents in Dar es Salaam.

⁴Occupation missing for 2 adolescents in Ibadan.

(63%) and Dar es Salaam (89%). Parental or familial will was the second common driver for vaccination, selected by over 60% of adolescents in all areas except Addis Ababa (45%) and Dodoma (25%). Doctors' suggestions were the third common motivation for vaccination, chosen by over 40% of adolescents in all areas except Dodoma (16%) and Dar es Salaam (35%). Among adolescents who were definitely not or possibly not willing to receive COVID-19 vaccines, the leading reasons for hesitancy were perceived low necessity (selected by 47% of adolescents overall), concerns about the safety of the vaccine (selected by 46% overall), and concerns about the effectiveness of the vaccine (selected by 12% overall). Personal liberty concerns, the influence of conspiracy theories, religious reasons, and fears of getting unlicensed, experimental, or worse-quality vaccines were not the main reasons for hesitancy, each cited by less than 3% of adolescents.

Table 2 Willingness to receive the COVID-19 vaccine among adolescents in a phone-based survey in five sub-Saharan African countries, 2021¹

	Burk	ina Faso	Ethi	opia	Ghana	Nig	eria	Tanz	zania	
	Rural	Urban	Rural	Urban	Rural	Rural	Urban	Rural	Urban	Total
	Nouna	Ouagadougou	Kersa	Addis	Kintampo	Ibadan	Lagos	Dodoma	Dar es	
				Ababa					Salaam	
Number of adolescents, N	309	300	300	308	300	319	347	318	302	2803
Having heard of COVID-19 vaccine, 2 N (%)	225 (73.5)	270 (90.0)	165 (56.9)	303 (98.4)	261 (87.9)	280 (90.0)	337 (97.1)	267 (84.0)	295 (98.0)	2403 (86.5)
Willingness to receive COVID-19 vaccine if it were available now, ^{3,4}										
N (%)										
Would definitely not get vaccinated	30 (13.3)	71 (26.4)	18 (10.9)	89 (29.4)	92 (35.3)	45 (16.1)	176 (52.2)	210 (78.7)	198 (67.1)	929 (38.7)
Would definitely get vaccinated	156 (69.3)	179 (66.5)	141 (85.5)	191 (63.0)	136 (52.1)	212 (76.0)	123 (36.5)	32 (12.0)	72 (24.4)	1242 (51.7)
Maybe/unsure/undecided	39 (17.3)	19 (7.1)	6 (3.6)	23 (7.6)	33 (12.6)	22 (7.9)	38 (11.3)	25 (9.4)	25 (8.5)	230 (9.6)
Reasons for getting the COVID-19 vaccine, 5,6 N (%)										
To keep self and family safe	182 (93.3)	195 (98.5)	143 (97.3)	212 (99.1)	156 (92.3)	225 (96.2)	155 (96.3)	36 (63.2)	86 (88.7)	1390 (94.4)
Parents' or family's will	172 (88.2)	174 (87.9)	106 (72.1)	96 (44.9)	125 (74.0)	189 (80.8)	98 (60.9)	14 (24.6)	69 (71.1)	1043 (70.9)
Because doctor suggested	156 (80.0)	192 (97.0)	66 (44.9)	96 (44.9)	119 (70.4)	172 (73.5)	76 (47.2)	9 (15.8)	34 (35.1)	920 (62.5)
Reasons for not getting the COVID-19 vaccine, ^{5,7} N (%)										
Perceived low necessity of being vaccinated	48 (71.6)	52 (60.5)	15 (62.5)	37 (33.3)	20 (18.0)	22 (36.1)	81 (38.2)	168 (90.8)	59 (26.8)	502 (46.6)
Concerns about effectiveness of the vaccine	9 (13.4)	28 (32.6)	0 (0.0)	23 (20.7)	7 (6.3)	7 (11.5)	40 (18.9)	2 (1.1)	8 (3.6)	124 (11.5)
Concerns about safety of the vaccine	24 (35.8)	55 (64.0)	9 (37.5)	74 (66.7)	59 (53.2)	33 (54.1)	146 (68.9)	6 (3.2)	88 (40.0)	494 (45.9)

Fear of getting unlicensed/experimental/worse-quality vaccines	2 (3.0)	1 (1.2)	0 (0.0)	4 (3.6)	3 (2.7)	1 (1.6)	11 (5.2)	1 (0.5)	2 (0.9)	25 (2.3)
Religious reasons	0 (0.0)	0 (0.0)	0 (0.0)	12 (10.8)	1 (0.9)	0 (0.0)	2 (0.9)	0 (0.0)	1 (0.5)	16 (1.5)
Influence of conspiracy theories	1 (1.5)	1 (1.2)	0 (0.0)	5 (4.5)	13 (11.7)	2 (3.3)	4 (1.9)	0 (0.0)	0 (0.0)	26 (2.4)
Personal liberty concerns	0 (0.0)	2 (2.3)	0 (0.0)	2 (1.8)	5 (4.5)	0 (0.0)	1 (0.5)	2 (1.1)	3 (1.4)	15 (1.4)

²⁵³ ¹ Values are counts (percentages) for categorical variables. 254

263

264

265

266

267

268

269

270

271

Perceptions of COVID-19 vaccines

The percentage of adolescents who perceived COVID-19 vaccines to be very safe or somewhat safe among the general population ranged from 38% in Dodoma to 76% in Kersa and Addis Ababa (**Table 3**). Similarly, the percentage of adolescents perceiving COVID-19 vaccines as very safe or somewhat safe among children and adolescents varied from 33% in Dodoma to 77% in Kersa. In terms of the perceived effectiveness of COVID-19 vaccines among the general population, 39% of participants in Dodoma to 80% of participants in Kersa perceived COVID-19 vaccines to be very effective or somewhat effective in preventing COVID-19 infection. Overall, 46% of adolescents could not identify any possible side effects of COVID-19 vaccines, and 27% believed that there were no side effects from the vaccines.

272 **Table 3** Perceptions of the COVID-19 vaccine among adolescents in a phone-based survey in five sub-Saharan African countries. 2021

 ,					,				
Burkina Faso		Ethi	opia	Ghana	Nigeria		Tanzania		
Rural	Urban	Rural	Urban	Rural	Rural	Urban	Rural	Urban	Total

² Missing for 3 adolescents in Nouna, 10 adolescents in Kersa, 8 adolescents in Ibadan, 1 adolescent in Dar es Salaam, and 3 adolescents in Kintampo.

²⁵⁵ ³ Percentages may not add up to 100% due to rounding. 256

⁴ Among adolescents who have heard of COVID-19 vaccines. Missing for 1 adolescent in Ouagadougou and 1 adolescent in Ibadan.

²⁵⁷ 258 ⁵ Counts and percentages do not add up to the total because the selection of multiple reasons was allowed.

⁶ Counts and percentages are among adolescents who would definitely get vaccinated and who were unsure/undecided.

²⁵⁹ ⁷ Counts and percentages are among adolescents who would definitely not get vaccinated and who were unsure/undecided. Missing for 2 adolescents in Nouna, 4 adolescents in 260

Ouagadougou, 1 adolescent in Addis Ababa, 6 adolescents in Ibadan, 2 adolescents in Lagos, 3 adolescents in Dar es Salaam, 50 adolescents in Dodoma, and 14 adolescents in

²⁶¹ Kintampo.

	Nouna	Ouagadougou	Kersa	Addis Ababa	Kintampo	Ibadan	Lagos	Dodoma	Dar es Salaam	
Number of adolescents, N	309	300	300	308	300	319	347	318	302	2803
Perceived safety of the COVID-19 vaccine in general, ^{2,3} N (%)										
Very safe	135 (43.7)	119 (39.9)	224 (74.7)	50 (16.2)	67 (22.3)	171 (53.6)	97 (28.0)	46 (14.5)	92 (30.5)	1001 (35.7)
Somewhat safe	68 (22.0)	56 (18.8)	4 (1.3)	184 (59.7)	69 (23.0)	61 (19.1)	90 (25.9)	76 (23.9)	57 (18.9)	665 (23.7)
Not very safe	50 (16.2)	54 (18.1)	6 (2.0)	28 (9.1)	42 (14.0)	24 (7.5)	83 (23.9)	80 (25.2)	28 (9.3)	395 (14.1)
Not safe at all	5 (1.6)	20 (6.7)	2 (0.7)	25 (8.1)	16 (5.3)	12 (3.8)	28 (8.1)	19 (6.0)	54 (17.9)	181 (6.5)
Do not know	51 (16.5)	49 (16.4)	64 (21.3)	21 (6.8)	106 (35.3)	51 (16.0)	49 (14.1)	97 (30.5)	71 (23.5)	559 (20.0)
Perceived safety of the COVID-19 vaccine among children and adolescents, 2.4 N (%)										
Very safe	131 (42.4)	91 (31.4)	230 (76.7)	67 (21.8)	50 (16.7)	151 (47.3)	93 (26.8)	39 (12.3)	84 (27.8)	936 (33.5)
Somewhat safe	65 (21.0)	62 (21.4)	2 (0.7)	141 (45.8)	59 (19.7)	67 (21.0)	85 (24.5)	66 (20.8)	47 (15.6)	594 (21.3)
Not very safe	53 (17.2)	58 (20.0)	7 (2.3)	42 (13.6)	48 (16.0)	31 (9.7)	84 (24.2)	84 (26.5)	28 (9.3)	435 (15.6)
Not safe at all	7 (2.3)	25 (8.6)	2 (0.7)	30 (9.7)	27 (9.0)	11 (3.5)	30 (8.7)	31 (9.8)	66 (21.9)	229 (8.2)
Do not know	53 (17.2)	54 (18.6)	59 (19.7)	28 (9.1)	116 (38.7)	59 (18.5)	55 (15.9)	97 (30.6)	77 (25.5)	598 (21.4)
Perceived effectiveness of the COVID-19 vaccine in general, 2,5 N (%)										
Very effective	136 (44.0)	120 (40.8)	220 (73.3)	66 (21.4)	63 (21.0)	164 (51.4)	88 (25.4)	48 (15.2)	71 (23.5)	976 (34.9)
Somewhat effective	65 (21.0)	56 (19.1)	20 (6.7)	149 (48.4)	58 (19.3)	72 (22.6)	81 (23.3)	75 (23.8)	57 (18.9)	633 (22.7)
Not very effective	42 (13.6)	38 (12.9)	5 (1.7)	30 (9.7)	31 (10.3)	24 (7.5)	71 (20.5)	80 (25.4)	31 (10.3)	352 (12.6)
Not effective at all	6 (1.9)	20 (6.8)	2 (0.7)	21 (6.8)	16 (5.3)	5 (1.6)	25 (7.2)	19 (6.0)	54 (17.9)	168 (6.0)
Do not know	60 (19.4)	60 (20.4)	53 (17.7)	42 (13.6)	132 (44.0)	54 (16.9)	82 (23.6)	93 (29.5)	89 (29.5)	665 (23.8)
Perceived side effects of the COVID-19 vaccine, ^{6,7} N (%)										
No side effects	52 (16.8)	73 (24.4)	130 (43.3)	105 (34.1)	49 (16.3)	111 (34.8)	54 (15.6)	99 (31.3)	88 (29.1)	761 (27.2)
Fever	64 (20.7)	42 (14.1)	1 (0.3)	69 (22.4)	33 (11.0)	58 (18.2)	83 (23.9)	3 (1.0)	25 (8.3)	378 (13.5)
Body ache including sore arm	59 (19.1)	19 (6.4)	7 (2.3)	115 (37.3)	38 (12.7)	74 (23.2)	94 (27.1)	3 (1.0)	13 (4.3)	422 (15.1)
Nausea	54 (17.5)	22 (7.4)	1 (0.3)	51 (16.6)	10 (3.3)	11 (3.5)	19 (5.5)	0 (0.0)	6 (2.0)	174 (6.2)
Tiredness/exhaustion	62 (20.1)	38 (12.7)	7 (2.3)	76 (24.7)	24 (8.0)	73 (22.9)	69 (19.9)	0 (0.0)	10 (3.3)	359 (12.8)
Do not know any	183 (59.2)	158 (52.8)	158 (52.7)	41 (13.3)	179 (59.7)	109 (34.2)	124 (35.7)	203 (64.2)	119 (39.4)	1274 (45.5)

²⁷³ ¹ Values are counts (percentages) for categorical variables.

Self-reported determinants of willingness to receive vaccines 281

² Percentages may not add up to 100% due to rounding.

²⁷⁴ 275 276 ³ Missing for 2 adolescents in Ouagadougou.

⁴ Missing for 10 adolescents in Ouagadougou and 1 adolescent in Dodoma.

²⁷⁷ ⁵ Missing for 6 adolescents in Ouagadougou and 3 adolescents in Dodoma.

²⁷⁸ ⁶ Counts and percentages do not add up to the total because the selection of multiple reasons was allowed.

²⁷⁹ ⁷ Missing for 1 adolescent in Ouagadougou and 2 adolescents in Dodoma.

The percentage of adolescents whose willingness to receive COVID-19 vaccines would be affected by the vaccine's country of origin ranged from 15% in Ibadan to 44% in Lagos (**Table 4**). In descending order, the overall percentages of adolescents willing to receive COVID-19 vaccines developed by specific countries were 37% for the United States, 21% for China, 15% for Europe, 13% for Russia, and 11% for India. Overall, 29% of the participants would be more willing to receive a COVID-19 vaccine developed or tested in Africa, ranging from 15% in Ibadan to 48% in Kintampo. The individuals or groups that had the greatest impacts on the adolescents' willingness to receive COVID-19 vaccines were healthcare workers (60% overall), parents or family members (58% overall), and schoolteachers (46% overall). Religious leaders affected COVID-19 vaccine willingness for over 20% of adolescents in all areas (36% overall).

Table 4 Determinants of the willingness to receive the COVID-19 vaccine among adolescents in a phone-based survey in five sub-Saharan African countries, 2021¹

	Burkir	na Faso	Ethi	opia	Ghana	Nig	eria	Tanz	zania	
	Rural	Urban	Rural	Urban	Rural	Rural	Urban	Rural	Urban	Total
	Nouna	Ouagadou	Kersa	Addis	Kintampo	Ibadan	Lagos	Dodoma	Dar es	
		gou		Ababa					Salaam	
Number of adolescents, N	309	300	300	308	300	319	347	318	302	2803
Willingness affected by the vaccine's country of origin, 2,3 N (%)										
No	224 (72.5)	170 (56.7)	197 (65.7)	217 (70.5)	183 (61.4)	253 (79.3)	179 (51.7)	210 (68.2)	209 (69.2)	1842 (66.0)
Yes	75 (24.3)	118 (39.3)	58 (19.3)	86 (27.9)	88 (29.5)	48 (15.1)	152 (43.9)	49 (15.9)	66 (21.9)	740 (26.5)
Do not know	10 (3.2)	12 (4.0)	45 (15.0)	5 (1.6)	27 (9.1)	18 (5.6)	15 (4.3)	49 (15.9)	27 (8.9)	208 (7.5)
Willing to receive COVID-19 vaccine developed by the country, 4,5 N (%)										
United States	36 (42.4)	41 (31.5)	19 (18.5)	33 (36.3)	53 (46.9)	35 (53.0)	112 (67.1)	1 (1.1)	14 (15.1)	344 (36.6)
China	33 (38.8)	48 (36.9)	27 (26.2)	24 (26.4)	22 (19.5)	5 (7.6)	28 (16.8)	1 (1.1)	9 (9.7)	197 (21.0)
Russia	26 (30.6)	27 (20.8)	6 (5.8)	12 (13.2)	39 (34.5)	4 (6.1)	10 (6.0)	0 (0.0)	1 (1.1)	125 (13.3)
India	15 (17.7)	26 (20.0)	3 (2.9)	6 (6.6)	29 (25.7)	4 (6.1)	18 (10.8)	1 (1.1)	2 (2.2)	104 (11.1)
Europe	18 (21.2)	18 (13.9)	9 (8.7)	12 (13.2)	29 (25.7)	14 (21.2)	33 (19.8)	0 (0.0)	3 (3.2)	136 (14.5)
Do not know	24 (28.2)	12 (9.2)	45 (43.7)	19 (20.9)	28 (24.8)	18 (27.3)	28 (16.8)	56 (61.5)	34 (36.6)	264 (28.1)
Willingness of receiving a COVID-19 vaccine developed or tested in										
Africa, ^{2,6} N (%)										
Would not affect willingness	167 (54.2)	123 (41.0)	187 (62.3)	194 (63.0)	122 (40.7)	227 (71.2)	187 (53.9)	196 (65.3)	179 (59.3)	1582 (56.8)

Would decrease willingness	13 (4.2)	24 (8.0)	3 (1.0)	48 (15.6)	15 (5.0)	27 (8.5)	62 (17.9)	6 (2.0)	0 (0.0)	198 (7.1)
Would increase willingness	111 (36.0)	138 (46.0)	70 (23.3)	58 (18.8)	143 (47.7)	49 (15.4)	86 (24.8)	55 (18.3)	103 (34.1)	813 (29.2)
Do not know	17 (5.5)	15 (5.0)	40 (13.3)	8 (2.6)	20 (6.7)	16 (5.0)	12 (3.5)	43 (14.3)	20 (6.6)	191 (6.9)
Willingness affected by individuals or groups, 4 N (%)										
Parents or family members	248 (80.3)	218 (72.7)	158 (52.7)	110 (35.7)	231 (77.0)	233 (73.0)	252 (72.6)	42 (13.2)	130 (43.1)	1622 (57.9)
Religious leaders	143 (46.3)	119 (39.7)	102 (34.0)	90 (29.2)	161 (53.7)	104 (32.6)	150 (43.2)	68 (21.4)	74 (24.5)	1011 (36.1)
Community/tribal leaders	113 (36.6)	104 (34.7)	83 (27.7)	89 (28.9)	141 (47.0)	61 (19.1)	66 (19.0)	21 (6.6)	19 (6.3)	697 (24.9)
Political leaders	63 (20.4)	131 (43.7)	75 (25.0)	49 (15.9)	115 (38.3)	49 (15.4)	56 (16.1)	27 (8.5)	47 (15.6)	612 (21.8)
Celebrities or social media influencers	38 (12.3)	68 (22.7)	21 (7.0)	61 (19.8)	83 (27.7)	51 (16.0)	64 (18.4)	12 (3.8)	30 (9.9)	428 (15.3)
Healthcare workers	211 (68.3)	226 (75.3)	158 (52.7)	172 (55.8)	222 (74.0)	238 (74.6)	244 (70.3)	136 (42.8)	81 (26.8)	1688 (60.2)
Schoolteachers	168 (54.4)	167 (55.7)	152 (50.7)	89 (28.9)	164 (54.7)	163 (51.1)	101 (29.1)	110 (34.6)	164 (54.3)	1278 (45.6)

¹ Values are counts (percentages) for categorical variables.

Trusted information sources and expectations of vaccines

The most highly trusted sources of information on COVID-19 vaccines for adolescents were television, radio, or newspaper (85% overall), medical professionals (83% overall), and governmental communications (74% overall) (S1 Table). The adolescents' willingness to participate in a COVID-19 vaccine trial ranged from 14% in Dodoma to 65% in Kersa. No more than 2% of the adolescents had already received a COVID-19 vaccine, except in Ibadan, where 13% had been vaccinated. Overall, 41% of the adolescents did not know when a COVID-19 vaccine would be made available to them. In particular, 70% of adolescents in Dodoma and 41% in Dar es Salaam thought that a COVID-19 vaccine would never be made available to them. Overall, 90% of adolescents believed that individuals should continue following COVID-19 preventative guidelines even after vaccines became available.

² Percentages may not add up to 100% due to rounding.

³ Missing for 1 adolescent in Lagos, 10 adolescents in Dodoma, and 2 adolescents in Kintampo.

⁴Counts and percentages do not add up to the total because the selection of multiple reasons was allowed.

⁵Counts and percentages are among adolescents whose willingness to take a COVID-19 vaccine may be affected by the vaccine's country of origin. Missing for 7 adolescents in Dodoma and 2 adolescents in Kintampo.

⁶ Missing for 1 adolescent in Nouna and 18 adolescents in Dodoma.

Potential determinants of COVID-19 vaccine hesitancy

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

Older age was associated with a lower prevalence of COVID-19 vaccine hesitancy (aPR: 0.98; 95% CI: 0.97, 1.00) (**Table 5**). Compared to girls, boys were 8% less likely to have vaccine hesitancy (aPR: 0.92; 95% CI: 0.86, 0.98). Compared to adolescents in Burkina Faso, adolescents in Ethiopia were similarly likely to have COVID-19 vaccine hesitancy (aPR: 0.91; 95% CI: 0.75, 1.11), adolescents in Ghana were 55% more likely to have COVID-19 vaccine hesitancy (aPR: 1.55; 95% CI: 1.28, 1.86), adolescents in Nigeria were 44% more likely to have COVID-19 vaccine hesitancy (aPR: 1.44; 95% CI: 1.23, 1.68), and adolescents in Tanzania were 142% more likely to have COVID-19 vaccine hesitancy (aPR: 2.42; 95% CI: 2.11, 2.78). Rural residence was associated with an 8% lower prevalence of vaccine hesitancy (aPR: 0.92; 95% CI: 0.85, 1.00). Compared to those who perceived COVID-19 vaccines to be very safe among children and adolescents, adolescents perceiving COVID-19 vaccines to be somewhat safe, not very safe, and not safe at all had 1.8 times (aPR: 1.83; 95% CI: 1.54, 2.16), 3.5 times (aPR: 3.50; 95% CI: 3.01, 4.06), and 3.6 times (aPR: 3.61; 95% CI: 3.10, 4.22) the prevalence of COVID-19 vaccine hesitancy, respectively. Similarly, compared to adolescents who believed that COVID-19 vaccines were very effective, adolescents who perceived COVID-19 vaccines to be somewhat effective, not very effective, and not effective at all had 1.9 times (aPR: 1.94; 95% CI: 1.66, 2.28), 3.4 times (aPR: 3.37; 95% CI: 2.91, 3.90), and 3.6 times (aPR: 3.59; 95% CI: 3.09, 4.18) the prevalence of vaccine hesitancy, respectively. Experiencing any current impacts of the COVID-19 pandemic on daily activities was associated with an 11% lower prevalence of COVID-19 vaccine hesitancy (aPR: 0.89; 95% CI: 0.81, 0.97). Currently receiving education, levels of psychological distress, perceived risk of exposure to COVID-19 during Round 1, and level of COVID-19 knowledge during Round 1 were not significantly associated with COVID-19 vaccine hesitancy.

Table 5 Potential determinants of COVID-19 vaccine hesitancy among adolescents in a phone-based survey in five sub-Saharan African countries, 2021¹

ants of COVID-19 vaccine hesitancy among adolescents in a phone-based survey		ccine hesitancy ²
	Unadjusted	Adjusted
	PR (95% CI)	aPR (95% CI)
Age, years	0.95 (0.93, 0.96)	0.98 (0.97, 1.00)
Male sex	0.84 (0.78, 0.92)	0.92 (0.86, 0.98)
Country		
Burkina Faso	1.00 (Ref)	1.00 (Ref)
Ethiopia	0.90 (0.75, 1.09)	0.91 (0.75, 1.11)
Ghana	1.49 (1.24, 1.78)	1.55 (1.28, 1.86)
Nigeria	1.42 (1.21, 1.65)	1.44 (1.23, 1.68)
Tanzania	2.53 (2.21, 2.89)	2.42 (2.11, 2.78)
Rural residence	0.82 (0.75, 0.89)	0.92 (0.85, 1.00)
Not currently receiving education	0.81 (0.70, 0.93)	1.04 (0.92, 1.19)
Perceived safety of the COVID-19 vaccine among children and adolescents		
Very safe	1.00 (Ref)	1.00 (Ref)
Somewhat safe	1.93 (1.61, 2.30)	1.83 (1.54, 2.16)
Not very safe	3.89 (3.34, 4.53)	3.50 (3.01, 4.06)
Not safe at all	4.64 (4.01, 5.38)	3.61 (3.10, 4.22)
Do not know	3.33 (2.85, 3.89)	2.82 (2.42, 3.30)
Perceived effectiveness of the COVID-19 vaccine		
Very effective	1.00 (Ref)	1.00 (Ref)
Somewhat effective	2.09 (1.77, 2.46)	1.94 (1.66, 2.28)
Not very effective	3.93 (3.39, 4.55)	3.37 (2.91, 3.90)
Not effective at all	4.69 (4.08, 5.40)	3.59 (3.09, 4.18)
Do not know	3.33 (2.87, 3.87)	2.82 (2.43, 3.28)
Current impacts of the COVID-19 pandemic on daily activities		
No impacts	1.00 (Ref)	1.00 (Ref)
Some impacts	1.17 (1.07, 1.28)	0.89 (0.81, 0.97)
Psychological distress ³		
No psychological distress	1.00 (Ref)	1.00 (Ref)
Mild psychological distress	0.96 (0.85, 1.09)	1.03 (0.93, 1.14)
Moderate psychological distress	0.93 (0.74, 1.16)	0.99 (0.82, 1.20)
Severe psychological distress	0.80 (0.45, 1.42)	0.89 (0.55, 1.43)
Perceived risk of exposure to COVID-19 during Round 1 ⁴		
No risk	1.00 (Ref)	1.00 (Ref)
Low risk	0.92 (0.68, 1.25)	0.87 (0.64, 1.18)
High risk	0.78 (0.55, 1.11)	0.84 (0.58, 1.21)
Very high risk	0.72 (0.41, 1.28)	0.70 (0.40, 1.24)
High knowledge score of COVID-19 during Round 1 ⁵	1.01 (0.80, 1.27)	0.90 (0.72, 1.14)

- 328 ¹ Values are prevalence ratios (95% confidence intervals) from log-binomial or modified Poisson models. The adjusted analyses controlled for age, sex, country, and rural 329 residence. PR, prevalence ratio; CI, confidence interval; aPR, adjusted prevalence ratio.
- 330 ² COVID-19 vaccine hesitancy was defined as a response of definitely not getting the COVID-19 vaccine, or a response of maybe, unsure, or undecided on whether to get the 331 COVID-19 vaccine if it were available now.
- 332 ³ Psychological distress was measured using the four-item Patient Health Questionnaire for Depression and Anxiety Scale. Each item had a numeric score of 0, 1, 2, and 3, and the 333 total score was computed by adding up the four items, resulting in a total score ranging from 0 to 12. The total score of psychological distress was categorized into none (total 334 score: 0 to 2), mild (total score: 3 to 5), moderate (total score: 6 to 8), and severe (total score: 9 to 12).
- ⁴ For adolescents in Burkina Faso, Ethiopia, and Nigeria who participated in the Round 1 survey.

341

335 336 337 338 ⁵ For adolescents in Burkina Faso, Ethiopia, and Nigeria who participated in the Round 1 survey. For each of the three domains of COVID-19 knowledge (symptoms, transmission, and prevention), a score was created based on the number of correct responses. The maximum scores for symptoms, transmission, and prevention were 10, 5, and 7, respectively. The three scores were then added to construct a total knowledge score of COVID-19 with a range from 0 to 22. A high knowledge score was defined as a total score of 18 or 339

Discussion

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

This multi-country survey finds high COVID-19 vaccine hesitancy among adolescents from the nine areas across five countries in sub-Saharan Africa. The level of hesitancy is exceptionally high in Tanzania. Individual characteristics that potentially increase vaccine hesitancy are female sex, perceived lack of safety, and perceived lack of effectiveness of COVID-19 vaccines. COVID-19 vaccine perceptions and hesitancy are influenced by social and cultural factors that vary considerably across settings [15-21]. Of note, a large sample of 13,426 participants from the general population in 19 countries showed high heterogeneity across countries in the determinants, and even the directions of associations, of vaccine acceptance [16]. This survey is, to our knowledge, the first study that examined the levels and determinants of COVID-19 vaccine hesitancy among adolescents across various settings in sub-Saharan Africa. While the proportion of adolescents with COVID-19 vaccine hesitancy is high across areas. considerable variation is also noted, ranging from 15% in Kersa to 88% in Dodoma. Previous studies in high- or upper-middle-income settings report similarly heterogeneous levels of hesitancy. A study in adolescents aged 12 to 15 years in Arkansas, United States, reported that 58% were hesitant about getting a COVID-19 vaccine [22]. A study among Canadian adolescents aged 14 to 17 years reported that 35% would not get a COVID-19 vaccine or were unsure [24]. Based on a survey conducted by the United States Centers for Disease Control and Prevention in April 2021, only 52% of unvaccinated adolescents aged 13 to 17 years would definitely or probably receive COVID-19 vaccination [12]. A study among Swedish adolescents showed that nearly one in three adolescents had not decided if they wanted to get a COVID-19 vaccine and that only 54% were willing to be vaccinated [25]. In a survey among Chinese

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

adolescents, 76% of the participants would accept future COVID-19 vaccination [10]. In our survey, the exceptionally high level of vaccine hesitancy in Dodoma and Dar es Salaam is perhaps attributable to the misconceptions regarding COVID-19 and its vaccination, partially exacerbated by misinformation among communities in 2020 and early 2021 [51, 52]. We find that healthcare providers are adolescents' most trusted individuals for information on COVID-19 vaccines and may have the greatest impact on the adolescents' willingness to vaccinate. Even in Tanzania, where vaccine hesitancy is high, over 60% of adolescents trust vaccine information from healthcare providers. Previous global surveys among the general population also consistently showed that health workers are the most trusted sources of guidance about COVID-19 vaccines [31]. A survey among Turkish adults reported that adults with higher trust in health professionals had more favorable attitudes towards COVID-19 vaccines [43]. Our survey also suggests that parents', friends', and schoolteachers' attitudes toward COVID-19 vaccination may influence adolescents' willingness to get vaccinated. Similarly, a diverse sample of adolescents in the United States showed that parent and peer norms were distinct predictors of adolescent willingness to receive vaccines [23]. Therefore, healthcare workers, parents, schoolteachers, and peers should be leveraged as advocates of COVID-19 vaccines. Efforts are needed to increase vaccine acceptance among healthcare workers and adult community members in general. Our survey finds that, in all study areas, over 40% of adolescents considered religious bodies or leaders a trusted source of information on COVID-19 vaccines and that religious

Our survey finds that, in all study areas, over 40% of adolescents considered religious bodies or leaders a trusted source of information on COVID-19 vaccines and that religious leaders affected COVID-19 vaccine willingness for over 20% of adolescents. There is a mixed body of evidence regarding religious influence on COVID-19 vaccine perceptions. A survey among Turkish adults found no significant associations between religious attitudes and COVID-

19 vaccine perceptions [34]. However, a survey in Pakistan showed a strong association between religious inhibitions (the belief that trust in God was sufficient to protect one from infection) and vaccine hesitancy in adults [36]. In our survey, for 15% of adolescents overall, vaccine willingness can be affected by celebrities and social media influencers. The uncritical consumption of social media may promote vaccine hesitancy [53]. In particular, emerging social media platforms may be used to spread anti-vaccination content that jeopardizes vaccine uptake, particularly for young people who are more likely to use such platforms [54]. Social media may also spread misinformation or conspiracy theories about COVID-19. In a survey among adults in Jordan, participants who believed in COVID-19 conspiracy theories were less likely to accept COVID-19 vaccines [37]. Future efforts are needed to leverage religious leaders and social media platforms as potential mechanisms for promoting adolescents' uptake of COVID-19 vaccines.

We report that the vaccine willingness of over 15% of adolescents in all areas is affected by the vaccine's country of origin, with COVID-19 vaccines developed in the United States the most accepted, followed by those developed in China; vaccines developed in Russia and India appear the least accepted. Among adults in Kazakhstan [35] and Zimbabwe [27], vaccine hesitancy is likewise influenced by the vaccines' country of origin or manufacturer. In Kazakhstan, for instance, 78% of the respondents had the highest confidence in German-produced vaccines and the lowest confidence in vaccines produced in India [35]. A global survey of 19,714 adults from 17 countries showed that 52% of the respondents would only accept COVID-19 vaccines from a specific country of origin [20]. In our survey, over 15% of the adolescents in all areas are more willing to receive COVID-19 vaccines developed or tested in

Africa, highlighting the importance of technology transfer for COVID-19 vaccines to increase sub-Saharan African countries' local capacities.

Concerns about the safety and effectiveness of COVID-19 vaccines are among the top reasons for hesitancy in this survey. Accordingly, perceived lack of safety and perceived lack of effectiveness strongly predict greater vaccine hesitancy. These findings align with previous studies among the adult population in both high-income and low- and middle-income settings [20, 31, 55]. A multi-country study assessed COVID-19 vaccine acceptance across 15 general population samples, including 44,260 individuals from the United States, Russia, and 10 LMICs in Asia, Africa, and South America [31]. The survey found that vaccine acceptance in LMICs is primarily driven by the desire for personal protection, and the most commonly cited reason for hesitancy was the concern about the side effects of the vaccine [31]. Among Chinese adolescents, those who thought that COVID-19 vaccines could protect them from COVID-19 infection and those who believed that vaccines were safe were more likely to be willing to receive COVID-19 vaccines [10]. Therefore, public health campaigns for adolescents and their guardians to boost COVID-19 vaccine uptake should emphasize that the vaccines are safe for adolescents and confer protection against COVID-19 infections [11].

We find that adolescent boys have less COVID-19 vaccine hesitancy than adolescent girls, consistent with existing evidence. Among Turkish adults, males had a higher probability of having positive attitudes toward COVID-19 vaccines [34]. Similarly, in a mixed-methods study in Sweden, girls had higher anxiety levels about the vaccine than boys. The specific mechanisms for the greater vaccine hesitancy among adolescent girls are unclear but may be related to the lower tendency of risk-taking among adolescent girls than among boys (i.e., considering receiving COVID-19 vaccines as a risk-taking behavior) [56]. These findings highlight the need

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

to address COVID-19 vaccine hesitancy, especially among adolescent girls. A study among 472,521 adults in Latin America and the Caribbean found that having depressive symptoms was associated with greater fear of the adverse effects of the COVID-19 vaccines [40], indicating that vaccine hesitancy for some individuals may be related to underlying mental health issues that must be addressed accordingly. We do not find associations between psychological distress and COVID-19 vaccine hesitancy. The impacts of the COVID-19 pandemic on the long-term mental well-being of sub-Saharan African adolescents need to be investigated further. The strengths of this study are the inclusion of multiple countries and cities in sub-Saharan Africa and the measurement of a wide array of potential determinants of COVID-19 vaccine hesitancy. A potential limitation of the study was that the study areas were selected based on existing connections and infrastructure, and the adolescents in each area were not selected probabilistically. Therefore, the results from this study are not expected to be representative of all adolescents in the country. Nevertheless, we increased the representativeness of the study population by including countries and areas geographically spread across sub-Saharan Africa. Therefore, the results provide important insights into the levels of determinants of COVID-19 vaccine hesitancy in sub-Saharan Africa. Another limitation is that, due to the nature of phone-based interviews, the adolescents included in most areas were those who resided in households with access to a mobile phone. Consequently, the sample might underrepresent adolescents from under-resourced households, which may affect generalizability. The presence of unreachable phone numbers and failures to pick up phone calls may also have impacts on the generalizability of the findings. In conclusion, we show that COVID-19 vaccine hesitancy among adolescents is high across the five sub-Saharan African countries, especially in Tanzania. COVID-19 vaccination

campaigns among sub-Saharan African adolescents must address adolescents' concerns and misconceptions about COVID-19 vaccines, especially regarding vaccination safety and effectiveness. It is unfortunate that, at the time of this survey, a considerable proportion of adolescents in sub-Saharan Africa did not yet know when COVID-19 vaccines would become available to them. It is crucial to ensure that vaccines are accessible should adolescents desire to be vaccinated. It rests upon the global medical community to get the shots into the arms of the often-neglected population of sub-Saharan African adolescents.

Acknowledgments

This work was supported by institutional support from Harvard T.H. Chan School of Public Health, Boston, MA; Harvard University Center for African Studies, Boston, MA; Heidelberg Institute of Global Health, Germany, and the George Washington University Milken Institute School of Public Health, Washington, DC.

We thank the study participants and data collectors for making this study possible. The survey team in Ghana is grateful for support from the Kintampo Health Research Centre of Ghana Health Service and the community leadership of Kintampo North Municipality and Kintampo South District.

References

- 475 1. COVID-19 Vaccines for Children and Teens: National Center for Immunization and
- 476 Respiratory Diseases (NCIRD), Division of Viral Diseases; 2022 [Available from:
- 477 https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html.
- 478 2. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al.
- 479 Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults:
- 480 A Systematic Review and Meta-analysis. JAMA pediatrics. 2021;175(2):143-56.
- 481 3. Zimet GD, Silverman RD, Fortenberry JD. Coronavirus Disease 2019 and Vaccination of
- 482 Children and Adolescents: Prospects and Challenges. The Journal of pediatrics. 2021;231:254-8.
- 483 4. Ng KF, Kothari T, Bandi S, Bird PW, Goyal K, Zoha M, et al. COVID-19 multisystem
- inflammatory syndrome in three teenagers with confirmed SARS-CoV-2 infection. Journal of
- 485 medical virology. 2020.
- 486 5. Idele P, Anthony D, Mofenson LM, Requejo J, You D, Luo C, et al. The evolving
- 487 epidemiologic and clinical picture of SARS-CoV-2 and COVID-19 disease in children and young 488 people. 2020.
- 489 6. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al.
- 490 Multisystem inflammatory syndrome in US children and adolescents. New England Journal of
- 491 Medicine. 2020;383(4):334-46.
- 492 7. Klass P, Ratner AJ. Vaccinating Children against Covid-19 The Lessons of Measles. The
- 493 New England journal of medicine. 2021;384(7):589-91.
- 494 8. United Nations Department of Economic and Social Affairs Population Division. World
- 495 Population Prospects 2019, Online Edition. Rev. 1. 2019.
- 496 9. World Health Organization. Achieving 70% COVID-19 Immunization Coverage by Mid-
- 497 2022 2021 [Available from: https://www.who.int/news/item/23-12-2021-achieving-70-covid-
- 498 19-immunization-coverage-by-mid-2022.
- 499 10. Cai H, Bai W, Liu S, Liu H, Chen X, Qi H, et al. Attitudes Toward COVID-19 Vaccines in
- 500 Chinese Adolescents. Frontiers in medicine. 2021;8:691079-.
- 501 11. Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. Safety, Immunogenicity, and Efficacy of
- 502 COVID-19 Vaccines in Children and Adolescents: A Systematic Review. Vaccines (Basel).
- 503 2021;9(10):1102.
- 504 12. Scherer AM, Gedlinske AM, Parker AM, Gidengil CA, Askelson NM, Petersen CA, et al.
- 505 Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of
- 506 Adolescents United States, April 15–23, 2021. Morbidity and Mortality Weekly Report.
- 507 2021;70(28):997-1003.
- 508 13. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. Vaccine.
- 509 2015;33(34):4161-4.
- 510 14. Qayum I. Top ten global health threats for 2019: the WHO list. Journal of Rehman
- 511 Medical Institute. 2019;5(2):01-2.
- 512 15. Ekwebelem OC, Yunusa I, Onyeaka H, Ekwebelem NC, Nnorom-Dike O. COVID-19 vaccine
- rollout: will it affect the rates of vaccine hesitancy in Africa? Public health (London).
- 514 2021;197:e18-e9.

- 515 16. Lazarus JV, Wyka K, Rauh L, Rabin K, Ratzan S, Gostin LO, et al. Hesitant or Not? The
- 516 Association of Age, Gender, and Education with Potential Acceptance of a COVID-19 Vaccine: A
- 517 Country-level Analysis. Journal of health communication. 2020;25(10):799-807.
- 518 17. Wake AD. The Willingness to Receive COVID-19 Vaccine and Its Associated Factors:
- 519 "Vaccination Refusal Could Prolong the War of This Pandemic" A Systematic Review. Risk
- management and healthcare policy. 2021;14:2609-23.
- 521 18. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of
- 522 Vaccine Acceptance Rates. Vaccines (Basel). 2021;9(2):160.
- 523 19. Wake AD. The Acceptance Rate Toward COVID-19 Vaccine in Africa: A Systematic
- Review and Meta-analysis. Global pediatric health. 2021;8:2333794-X211048738.
- 525 20. Wong LP, Alias H, Danaee M, Ahmed J, Lachyan A, Cai CZ, et al. COVID-19 vaccination
- intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17
- 527 countries. Infectious diseases of poverty. 2021;10(1):1-122.
- 528 21. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of
- 529 potential acceptance of a COVID-19 vaccine. Nature medicine. 2021;27(2):225-8.
- 530 22. Willis DE, Presley J, Williams M, Zaller N, McElfish PA. COVID-19 vaccine hesitancy
- among youth. Human vaccines & immunotherapeutics.ahead-of-print(ahead-of-print):1-3.
- 532 23. Rogers AA, Cook RE, Button JA. Parent and Peer Norms are Unique Correlates of COVID-
- 533 19 Vaccine Intentions in a Diverse Sample of U.S. Adolescents. Journal of adolescent health.
- 534 2021.
- 535 24. Afifi TO, Salmon S, Taillieu T, Stewart-Tufescu A, Fortier J, Driedger SM. Older
- adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for
- informing public health strategies. Vaccine. 2021;39(26):3473-9.
- 538 25. Nilsson S, Mattson J, Berghammer M, Brorsson AL, Forsner M, Jenholt Nolbris M, et al.
- To be or not to be vaccinated against COVID-19 The adolescents' perspective A mixed-
- methods study in Sweden. Vaccine: X. 2021;9:100117-.
- 26. Carcelen AC, Prosperi C, Mutembo S, Chongwe G, Mwansa FD, Ndubani P, et al. COVID-
- 19 vaccine hesitancy in Zambia: a glimpse at the possible challenges ahead for COVID-19
- vaccination rollout in sub-Saharan Africa. Human vaccines & immunotherapeutics.ahead-of-
- 544 print(ahead-of-print):1-6.
- 545 27. McAbee L, Tapera O, Kanyangarara M. Factors Associated with COVID-19 Vaccine
- Intentions in Eastern Zimbabwe: A Cross-Sectional Study. Vaccines (Basel). 2021;9(10):1109.
- 547 28. Echoru I, Ajambo PD, Keirania E, Bukenya EEM. Sociodemographic factors associated
- 548 with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in
- 549 western Uganda. BMC public health. 2021;21(1):1106-.
- 550 29. Dinga JN, Sinda LK, Titanji VPK. Assessment of Vaccine Hesitancy to a COVID-19 Vaccine
- in Cameroonian Adults and Its Global Implication. Vaccines (Basel). 2021;9(2):175.
- 552 30. Acheampong T, Akorsikumah EA, Osae-Kwapong J, Khalid M, Appiah A, Amuasi JH.
- 553 Examining Vaccine Hesitancy in Sub-Saharan Africa: A Survey of the Knowledge and Attitudes
- among Adults to Receive COVID-19 Vaccines in Ghana. Vaccines (Basel). 2021;9(8):814.
- 555 31. Solís Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. COVID-19
- vaccine acceptance and hesitancy in low- and middle-income countries. Nature medicine.
- 557 2021;27(8):1385-94.

- 558 32. Adebisi YA, Alaran AJ, Bolarinwa OA, Akande-Sholabi W, Lucero-Prisno Iii DE. When it is
- available, will we take it? Social media users' perception of hypothetical COVID-19 vaccine in
- Nigeria. The Pan African medical journal. 2021;38:230-.
- 33. Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al. Acceptance of a
- 562 COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. Frontiers in public
- 563 health. 2020;8:381-.
- 564 34. Kilic M, Ustundag Ocal N, Uslukilic G. The relationship of Covid-19 vaccine attitude with
- 565 life satisfaction, religious attitude and Covid-19 avoidance in Turkey. Human vaccines &
- 566 immunotherapeutics. 2021;17(10):3384-93.
- 567 35. Issanov A, Akhmetzhanova Z, Riethmacher D, Aljofan M. Knowledge, attitude, and
- 568 practice toward COVID-19 vaccination in Kazakhstan: a cross-sectional study. Human vaccines &
- 569 immunotherapeutics. 2021;17(10):3394-400.
- 570 36. Ahmed TF, Ahmed A, Ahmed S, Ahmed HU. Understanding COVID-19 vaccine
- acceptance in Pakistan: an echo of previous immunizations or prospect of change? Expert
- 572 review of vaccines. 2021;20(9):1185-93.
- 573 37. El-Elimat T, AbuAlSamen MM, Almomani BA, Al-Sawalha NA, Alali FQ. Acceptance and
- attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan. PloS one.
- 575 2021;16(4):e0250555-e.
- 576 38. Bagateli LE, Saeki EY, Fadda M, Agostoni C, Marchisio P, Milani GP. COVID-19 Vaccine
- 577 Hesitancy among Parents of Children and Adolescents Living in Brazil. Vaccines (Basel).
- 578 2021;9(10):1115.
- 579 39. Abdulah DM. Prevalence and correlates of COVID-19 vaccine hesitancy in the general
- 580 public in Iraqi Kurdistan: A cross-sectional study. Journal of medical virology. 2021;93(12):6722-
- 581 31.
- 582 40. Urrunaga-Pastor D, Bendezu-Quispe G, Herrera-Añazco P, Uyen-Cateriano A, Toro-
- 583 Huamanchumo CJ, Rodriguez-Morales AJ, et al. Cross-sectional analysis of COVID-19 vaccine
- intention, perceptions and hesitancy across Latin America and the Caribbean. Travel medicine
- 585 and infectious disease. 2021;41:102059-.
- 586 41. Elhadi M, Alsoufi A, Alhadi A, Hmeida A, Alshareea E, Dokali M, et al. Knowledge,
- 587 attitude, and acceptance of healthcare workers and the public regarding the COVID-19 vaccine:
- a cross-sectional study. BMC public health. 2021;21(1):955-.
- 589 42. Kumari A, Ranjan P, Chopra S, Kaur D, Kaur T, Kalanidhi KB, et al. What Indians Think of
- 590 the COVID-19 vaccine: A qualitative study comprising focus group discussions and thematic
- analysis. Diabetes & metabolic syndrome clinical research & reviews. 2021;15(3):679-82.
- 592 43. Karabela ŞN, Coşkun F, Hoşgör H. Investigation of the relationships between perceived
- 593 causes of COVID-19, attitudes towards vaccine and level of trust in information sources from
- the perspective of Infodemic: the case of Turkey. BMC public health. 2021;21(1):1195-.
- 595 44. Hervish A, Clifton D. adolescents and Young people in Sub-Saharan Africa: opportunities
- 596 and challenges: UNFPA; 2012.
- 597 45. Hemler EC, Korte ML, Lankoande B, Millogo O, Assefa N, Chukwu A, et al. Design and
- 598 Field Methods of the ARISE Network COVID-19 Rapid Monitoring Survey. The American journal
- of tropical medicine and hygiene. 2021;105(2):310.

- 600 46. Darling AM, Assefa N, Bärnighausen T, Berhane Y, Canavan CR, Guwatudde D, et al.
- 601 Design and field methods of the ARISE Network Adolescent Health Study. Tropical Medicine &
- 602 International Health. 2020;25(1):5-14.
- 603 47. Leyna GH, Berkman LF, Njelekela MA, Kazonda P, Irema K, Fawzi W, et al. Profile: the
- Dar Es Salaam health and demographic surveillance system (Dar es Salaam HDSS). International
- 605 Journal of Epidemiology. 2017;46(3):801-8.
- 606 48. Wang D, Chukwu A, Millogo O, Assefa N, James C, Young T, et al. The COVID-19
- 607 Pandemic and Adolescents' Experience in Sub-Saharan Africa: A Cross-Country Study Using a
- Telephone Survey. The American journal of tropical medicine and hygiene. 2021;105(2):331-41.
- 609 49. Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety and
- depression: the PHQ-4. Psychosomatics. 2009;50(6):613-21.
- 50. Zou G. A modified poisson regression approach to prospective studies with binary data.
- American journal of epidemiology. 2004;159(7):702-6.
- 613 51. Makoni M. Tanzania refuses COVID-19 vaccines. The Lancet (British edition).
- 614 2021;397(10274):566-.
- 615 52. Buguzi S. Covid-19: Counting the cost of denial in Tanzania. BMJ (Online).
- 616 2021;373:n1052-n.
- 617 53. Allington D, McAndrew S, Moxham-Hall VL, Duffy B. Media usage predicts intention to
- be vaccinated against SARS-CoV-2 in the US and the UK. Vaccine. 2021;39(18):2595-603.
- 619 54. Basch CH, Meleo-Erwin Z, Fera J, Jaime C, Basch CE. A global pandemic in the time of
- of viral memes: COVID-19 vaccine misinformation and disinformation on TikTok. Human vaccines
- 621 & immunotherapeutics. 2021;17(8):2373-7.
- 622 55. Bono SA, Faria de Moura Villela E, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors
- 623 Affecting COVID-19 Vaccine Acceptance: An International Survey among Low-and Middle-
- 624 Income Countries. Vaccines (Basel). 2021;9(5):515.
- 625 56. Reniers RLEP, Murphy L, Lin A, Bartolome SP, Wood SJ. Risk Perception and Risk-Taking
- 626 Behaviour during Adolescence: The Influence of Personality and Gender. PloS one.
- 627 2016;11(4):e0153842-e.

Supporting information

S1 Table. Trusted information sources and expectations about the COVID-19 vaccine among adolescents

in a phone-based survey in five sub-Saharan African countries, 2021